Directly interrupting NF-κB pathway is one option of therapeutic strategy, and lenalidomide, which is used as the immunomodulatory agent treating multiple myeloma (MM), was proved to have anti-tumor effects through downregulating IRF-4 in ABC-DLBCL cell lines [6]. The gene discussed is NFKB1; the disease is neoplasm.